-
1
-
-
84937806975
-
Treatment and outcome of primary and secondary thrombotic microangiopathies
-
PID: 26183157
-
Eskazan AE, Salihoglu A (2015) Treatment and outcome of primary and secondary thrombotic microangiopathies. Am J Nephrol 41(6):427–428
-
(2015)
Am J Nephrol
, vol.41
, Issue.6
, pp. 427-428
-
-
Eskazan, A.E.1
Salihoglu, A.2
-
2
-
-
0034099646
-
Management of thrombotic thrombocytopenic purpura
-
COI: 1:STN:280:DC%2BD3czksFequw%3D%3D, PID: 10886194
-
Rock GA (2000) Management of thrombotic thrombocytopenic purpura. Br J Haematol 109(3):496–507
-
(2000)
Br J Haematol
, vol.109
, Issue.3
, pp. 496-507
-
-
Rock, G.A.1
-
3
-
-
84929994371
-
How I treat refractory thrombotic thrombocytopenic purpura
-
COI: 1:CAS:528:DC%2BC2MXhtFCmsb%2FF, PID: 25784681
-
Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125(25):3860–3867
-
(2015)
Blood
, vol.125
, Issue.25
, pp. 3860-3867
-
-
Sayani, F.A.1
Abrams, C.S.2
-
4
-
-
84871810864
-
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura
-
COI: 1:CAS:528:DC%2BC3sXlvFahsw%3D%3D, PID: 23281998
-
Shortt J, Oh DH, Opat SS (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 368(1):90–92
-
(2013)
N Engl J Med
, vol.368
, Issue.1
, pp. 90-92
-
-
Shortt, J.1
Oh, D.H.2
Opat, S.S.3
-
5
-
-
84906225926
-
Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report
-
PID: 24655327
-
Yates S, Matevosyan K, Rutherford C et al (2014) Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion 54(8):2064–2067
-
(2014)
Transfusion
, vol.54
, Issue.8
, pp. 2064-2067
-
-
Yates, S.1
Matevosyan, K.2
Rutherford, C.3
-
6
-
-
84896697168
-
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura
-
COI: 1:CAS:528:DC%2BC2cXjslWmurY%3D, PID: 24345005
-
Mazepa MA, Raval JS, Moll S et al (2014) Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 164(6):900–902
-
(2014)
Br J Haematol
, vol.164
, Issue.6
, pp. 900-902
-
-
Mazepa, M.A.1
Raval, J.S.2
Moll, S.3
-
7
-
-
84890200058
-
Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib
-
PID: 24118335
-
van Balen T, Schreuder MF, de Jong H et al (2014) Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 92(1):80–82
-
(2014)
Eur J Haematol
, vol.92
, Issue.1
, pp. 80-82
-
-
van Balen, T.1
Schreuder, M.F.2
de Jong, H.3
-
8
-
-
84963603723
-
Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib
-
Patel PP, Becker J, Freyer C et al (2016) Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. Transfusion. doi:10.1111/trf.13465
-
(2016)
Transfusion
-
-
Patel, P.P.1
Becker, J.2
Freyer, C.3
-
9
-
-
84974814364
-
Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura
-
PID: 27284100
-
Acedillo RR, Govind M, Kashgary A et al (2016) Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura. BMJ Case Rep. doi:10.1136/bcr-2016-215491
-
(2016)
BMJ Case Rep
-
-
Acedillo, R.R.1
Govind, M.2
Kashgary, A.3
-
10
-
-
84961802012
-
Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura
-
PID: 27009919
-
Patriquin CJ, Thomas MR, Dutt T et al (2016) Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. doi:10.1111/bjh.13993
-
(2016)
Br J Haematol
-
-
Patriquin, C.J.1
Thomas, M.R.2
Dutt, T.3
-
11
-
-
38349159575
-
Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006
-
COI: 1:CAS:528:DC%2BD1cXjtlyhtbY%3D, PID: 18028271
-
Nguyen L, Li X, Duvall D et al (2008) Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 48(2):349–357
-
(2008)
Transfusion
, vol.48
, Issue.2
, pp. 349-357
-
-
Nguyen, L.1
Li, X.2
Duvall, D.3
-
12
-
-
0025999820
-
Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients
-
COI: 1:STN:280:DyaK3M3oslOnuw%3D%3D, PID: 2062331
-
Bell WR, Braine HG, Ness PM et al (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325(6):398–403
-
(1991)
N Engl J Med
, vol.325
, Issue.6
, pp. 398-403
-
-
Bell, W.R.1
Braine, H.G.2
Ness, P.M.3
-
13
-
-
77951650730
-
Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study
-
COI: 1:CAS:528:DC%2BC3cXkvVCqu7w%3D, PID: 20033409
-
Balduini CL, Gugliotta L, Luppi M et al (2010) Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 89(6):591–596
-
(2010)
Ann Hematol
, vol.89
, Issue.6
, pp. 591-596
-
-
Balduini, C.L.1
Gugliotta, L.2
Luppi, M.3
-
14
-
-
84925010068
-
The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura
-
COI: 1:CAS:528:DC%2BC2MXkvVCgu7c%3D, PID: 25573992
-
Lim W, Vesely SK, George JN (2015) The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood 125(10):1526–1531
-
(2015)
Blood
, vol.125
, Issue.10
, pp. 1526-1531
-
-
Lim, W.1
Vesely, S.K.2
George, J.N.3
-
15
-
-
84989233357
-
The efficacy of vincristine in the treatment of patients with relapsed/refractory thrombotic thrombocytopenic purpura
-
[abstract]
-
Ongoren Aydin S, Sadri S, Apaydin T et al (2014) The efficacy of vincristine in the treatment of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Haematologica 99(s1):474 [abstract]
-
(2014)
Haematologica
, vol.99
, Issue.s1
, pp. 474
-
-
Ongoren Aydin, S.1
Sadri, S.2
Apaydin, T.3
-
16
-
-
84869161774
-
Thrombotic microangiopathies reference center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience
-
PID: 22404639
-
Beloncle F, Buffet M, Coindre J-P et al (2012) Thrombotic microangiopathies reference center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience. Transfusion 52(11):2436–2444
-
(2012)
Transfusion
, vol.52
, Issue.11
, pp. 2436-2444
-
-
Beloncle, F.1
Buffet, M.2
Coindre, J.-P.3
-
17
-
-
84880229426
-
Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature
-
PID: 23121663
-
Yilmaz M, Eskazan AE, Unsal A et al (2013) Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. Transfusion 53(7):1586–1593
-
(2013)
Transfusion
, vol.53
, Issue.7
, pp. 1586-1593
-
-
Yilmaz, M.1
Eskazan, A.E.2
Unsal, A.3
-
18
-
-
27244460395
-
Splenectomy for the treatment of thrombotic thrombocytopenic purpura
-
COI: 1:STN:280:DC%2BD2MvkvVGksQ%3D%3D, PID: 16115135
-
Kappers-Klunne MC, Wijermans P, Fijnheer R et al (2005) Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 130(5):768–776
-
(2005)
Br J Haematol
, vol.130
, Issue.5
, pp. 768-776
-
-
Kappers-Klunne, M.C.1
Wijermans, P.2
Fijnheer, R.3
-
19
-
-
84892481567
-
Cancer Care Ontario Hematology Disease Site Group. Bortezomib in multiple myeloma: a practice guideline
-
COI: 1:STN:280:DC%2BC2c3kslOlsA%3D%3D
-
Kouroukis CT, Baldassarre FG, Haynes AE et al (2014) Cancer Care Ontario Hematology Disease Site Group. Bortezomib in multiple myeloma: a practice guideline. Clin Oncol (R Coll Radiol) 26(2):110–119
-
(2014)
Clin Oncol (R Coll Radiol)
, vol.26
, Issue.2
, pp. 110-119
-
-
Kouroukis, C.T.1
Baldassarre, F.G.2
Haynes, A.E.3
-
20
-
-
67650462779
-
Clinical development of novel proteasome inhibitors for cancer treatment
-
COI: 1:CAS:528:DC%2BD1MXns1eru7s%3D, PID: 19505187
-
Yang H, Zonder JA, Dou QP (2009) Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs 18(7):957–971
-
(2009)
Expert Opin Investig Drugs
, vol.18
, Issue.7
, pp. 957-971
-
-
Yang, H.1
Zonder, J.A.2
Dou, Q.P.3
-
21
-
-
84907966802
-
Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management
-
Vincent RS (2014) Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(10):999–1009
-
(2014)
Am J Hematol
, vol.89
, Issue.10
, pp. 999-1009
-
-
Vincent, R.S.1
-
23
-
-
84947125878
-
Bortezomib in kidney transplantation
-
COI: 1:CAS:528:DC%2BC2MXhvVarsbjF, PID: 26536428
-
Shah N, Meouchy J, Qazi Y (2015) Bortezomib in kidney transplantation. Curr Opin Organ Transplant 20(6):652–656
-
(2015)
Curr Opin Organ Transplant
, vol.20
, Issue.6
, pp. 652-656
-
-
Shah, N.1
Meouchy, J.2
Qazi, Y.3
-
24
-
-
84865593513
-
Bortezomib for acute antibody-mediated rejection in liver transplantation
-
COI: 1:CAS:528:DC%2BC38XhsVyrurvK, PID: 22681986
-
Paterno F, Shiller M, Tillery G et al (2012) Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 12(9):2526–2531
-
(2012)
Am J Transplant
, vol.12
, Issue.9
, pp. 2526-2531
-
-
Paterno, F.1
Shiller, M.2
Tillery, G.3
-
25
-
-
77952817334
-
Management of treatment-related adverse events in patients with multiple myeloma
-
PID: 20472185
-
Mateos MV (2010) Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 36(Suppl 2):S24–S32
-
(2010)
Cancer Treat Rev
, vol.36
, pp. S24-S32
-
-
Mateos, M.V.1
-
26
-
-
84993814033
-
Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma
-
COI: 1:CAS:528:DC%2BC38XosFSis74%3D, PID: 23556118
-
Mateos MV, San Miguel JF (2012) Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 3(2):117–124
-
(2012)
Ther Adv Hematol
, vol.3
, Issue.2
, pp. 117-124
-
-
Mateos, M.V.1
San Miguel, J.F.2
-
27
-
-
30344470197
-
Drug-induced thrombotic microangiopathy
-
COI: 1:CAS:528:DC%2BD28XptlSgug%3D%3D, PID: 16388419
-
Zakarija A, Bennett C (2005) Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 31(6):681–690
-
(2005)
Semin Thromb Hemost
, vol.31
, Issue.6
, pp. 681-690
-
-
Zakarija, A.1
Bennett, C.2
-
28
-
-
56649121992
-
Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma
-
PID: 18636313
-
Morita R, Hashino S, Shirai S et al (2008) Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 88(2):248–250
-
(2008)
Int J Hematol
, vol.88
, Issue.2
, pp. 248-250
-
-
Morita, R.1
Hashino, S.2
Shirai, S.3
-
29
-
-
84865448833
-
Bortezomib-induced thrombotic thrombocytopaenic purpura
-
Mehta N, Saxena A, Niesvizky R (2012) Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep vol.2012
-
(2012)
BMJ Case Rep
, vol.2012
-
-
Mehta, N.1
Saxena, A.2
Niesvizky, R.3
-
30
-
-
79955040869
-
Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib
-
COI: 1:CAS:528:DC%2BC3MXhs1Gqsb3O, PID: 21507163
-
Moore H, Romeril K (2011) Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J 41(4):348–350
-
(2011)
Intern Med J
, vol.41
, Issue.4
, pp. 348-350
-
-
Moore, H.1
Romeril, K.2
-
31
-
-
84887211986
-
Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma
-
PID: 22826795
-
Salmenniemi U, Remes K (2012) Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 4(2):e13
-
(2012)
Hematol Rep
, vol.4
, Issue.2
-
-
Salmenniemi, U.1
Remes, K.2
-
32
-
-
84983060381
-
Proteasome inhibitor associated thrombotic microangiopathy
-
PID: 27286661
-
Yui JC, Van Keer J, Weiss BM et al (2016) Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. doi:10.1002/ajh.24447
-
(2016)
Am J Hematol
-
-
Yui, J.C.1
Van Keer, J.2
Weiss, B.M.3
-
33
-
-
84899046075
-
Bortezomib and heart failure: case-report and review of the French pharmacovigilance database
-
COI: 1:CAS:528:DC%2BC2cXmtFSgsL4%3D, PID: 23781941
-
Honton B, Despas F, Dumonteil N et al (2014) Bortezomib and heart failure: case-report and review of the French pharmacovigilance database. Fundam Clin Pharmacol 28(3):349–352
-
(2014)
Fundam Clin Pharmacol
, vol.28
, Issue.3
, pp. 349-352
-
-
Honton, B.1
Despas, F.2
Dumonteil, N.3
-
34
-
-
84875762528
-
Antibody depletion by bortezomib through blocking of antigen presentation
-
COI: 1:CAS:528:DC%2BC3sXls1aktbs%3D, PID: 23550684
-
Park SJ, Cheong HI, Shin JI (2013) Antibody depletion by bortezomib through blocking of antigen presentation. N Engl J Med 368(14):1364–1365
-
(2013)
N Engl J Med
, vol.368
, Issue.14
, pp. 1364-1365
-
-
Park, S.J.1
Cheong, H.I.2
Shin, J.I.3
-
35
-
-
33847662436
-
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib
-
COI: 1:CAS:528:DC%2BD2sXislSrtLs%3D, PID: 17349869
-
Subklewe M, Sebelin-Wulf K, Beier C et al (2007) Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 68(3):147–155
-
(2007)
Hum Immunol
, vol.68
, Issue.3
, pp. 147-155
-
-
Subklewe, M.1
Sebelin-Wulf, K.2
Beier, C.3
-
36
-
-
84871025410
-
Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura
-
COI: 1:CAS:528:DC%2BC3sXht1Cqtbs%3D, PID: 22486316
-
Bhagirath VC, Kelton JG, Moore J et al (2012) Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura. Transfusion 52(12):2517–2523
-
(2012)
Transfusion
, vol.52
, Issue.12
, pp. 2517-2523
-
-
Bhagirath, V.C.1
Kelton, J.G.2
Moore, J.3
-
37
-
-
84904127650
-
French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
-
COI: 1:CAS:528:DC%2BC2cXht1WktbrO, PID: 24869941
-
Hie M, Gay J, Galicier L et al (2014) French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124(2):204–210
-
(2014)
Blood
, vol.124
, Issue.2
, pp. 204-210
-
-
Hie, M.1
Gay, J.2
Galicier, L.3
-
38
-
-
84865171981
-
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
-
COI: 1:CAS:528:DC%2BC38XhsFertrfF, PID: 22802322
-
Sonneveld P, Schmidt-Wolf IG, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30(24):2946–2955
-
(2012)
J Clin Oncol
, vol.30
, Issue.24
, pp. 2946-2955
-
-
Sonneveld, P.1
Schmidt-Wolf, I.G.2
van der Holt, B.3
|